Label: CREDELIO- lotilaner tablet, chewable
-
NDC Code(s):
58198-5451-1,
58198-5451-2,
58198-5451-3,
58198-5451-4, view more58198-5451-6, 58198-5451-7, 58198-5452-1, 58198-5452-2, 58198-5452-3, 58198-5452-4, 58198-5452-5, 58198-5452-6, 58198-5452-7, 58198-5454-1, 58198-5454-2, 58198-5454-3, 58198-5454-4, 58198-5454-6, 58198-5454-7, 58198-5456-1, 58198-5456-2, 58198-5456-3, 58198-5456-4, 58198-5456-5, 58198-5456-6, 58198-5456-7, 58198-5458-1, 58198-5458-2, 58198-5458-3, 58198-5458-4, 58198-5458-5, 58198-5458-6, 58198-5458-7
- Packager: Elanco US Inc.
- Category: PRESCRIPTION ANIMAL DRUG LABEL
- DEA Schedule: None
- Marketing Status: New Animal Drug Application
Drug Label Information
Updated August 20, 2021
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
- SPL UNCLASSIFIED SECTION
-
Description:
CREDELIO (lotilaner) is a beef-flavored, chewable tablet for oral administration to dogs and puppies according to their weight. Each chewable tablet is formulated to provide a minimum lotilaner dosage of 9 mg/lb (20 mg/kg).
Lotilaner has the chemical composition of 5-[(5S)-4,5-dihydro-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-2-thiophenecarboxamide.
-
Indications:
CREDELIO kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick) and Rhipicephalus sanguineus (brown dog tick)] for one month in dogs and puppies 8 weeks of age and older, and weighing 4.4 pounds or greater.
- Dosage and Administration:
-
Dosage Schedule:
Body Weight Lotilaner Per Chewable Tablet (mg) Chewable Tablets Administered 4.4 to 6.0 lbs 56.25 One 6.1 to 12.0 lbs 112.5 One 12.1 to 25.0 lbs 225 One 25.1 to 50.0 lbs 450 One 50.1 to 100.0 lbs 900 One Over 100.0 lbs Administer the appropriate combination of chewable tablets CREDELIO must be administered with food (see Clinical Pharmacology).
Treatment with CREDELIO can begin at any time of the year and can continue year-round without interruption.
- Contraindications:
- Warnings:
-
Precautions:
Lotilaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders.
The safe use of CREDELIO in breeding, pregnant or lactating dogs has not been evaluated.
-
Adverse Reactions:
In a well-controlled U.S. field study, which included 284 dogs (198 dogs treated with CREDELIO and 86 dogs treated with an oral active control), there were no serious adverse reactions.
Over the 90-day study period, all observations of potential adverse reactions were recorded. Reactions that occurred at an incidence of 1% or greater are presented in the following table.
Dogs with Adverse Reactions in the Field Study *Two geriatric dogs developed mildly elevated BUN (34 to 54 mg/dL; reference range: 6 to 31 mg/dL) during the study. One of these dogs also developed polyuria and a mildly elevated potassium (6.5 mEq/L; reference range: 3.6 to 5.5 mEq/L) and phosphorous (6.4 mg/dL; reference range: 2.5 to 6.0 mg/dL). The other dog also developed a mildly elevated creatinine (1.7 to 2.0 mg/dL; reference range: 0.5 to 1.6 mg/dL) and weight loss.
Adverse Reaction
(AR)CREDELIO Group: Number (and Percent) of Dogs with the AR
(n=198)Active Control Group:
Number (and Percent) of
Dogs with the AR
(n=86)Weight Loss 3 (1.5%) 2 (2.3%) Elevated Blood Urea Nitrogen (BUN) 2 (1.0%)* 0 (0.0%) Polyuria 2 (1.0%)* 0 (0.0%) Diarrhea 2 (1.0%) 2 (2.3%) In addition, one dog experienced intermittent head tremors within 1.5 hours of administration of vaccines, an ear cleaning performed by the owner, and its first dose of CREDELIO. The head tremors resolved within 24 hours without treatment. The owner elected to withdraw the dog from the study.
In an Australian field study, one dog with a history of seizures experienced seizure activity (tremors and glazed eyes) six days after receiving CREDELIO. The dog recovered without treatment and completed the study. In the U.S. field study, two dogs with a history of seizures received CREDELIO and experienced no seizures throughout the study.
In three well-controlled European field studies and one U.S. laboratory study, seven dogs experienced episodes of vomiting and four dogs experienced episodes of diarrhea between 6 hours and 3 days after receiving CREDELIO.
To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Elanco US Inc. at 1-888-545-5973. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.
-
Clinical Pharmacology:
Following oral administration of 43 mg/kg (approximately 1X the maximum labeled dose), peak lotilaner concentrations were achieved between 6 hours and 3 days in dogs 2 months of age and between 1 and 7 days in dogs 10 months of age. Dogs 2 months of age had a shorter elimination half-life (average of 9.6 days) than at 10 months of age (average of 28.4 days). Due to reduced drug bioavailability in the fasted state, CREDELIO must be administered with a meal or within 30 minutes after feeding.
-
Mode of Action:
Lotilaner is an ectoparasiticide belonging to the isoxazoline group. Lotilaner inhibits insect and acarine gamma-aminobutyric acid (GABA)-gated chloride channels. This inhibition blocks the transfer of chloride ions across cell membranes, which results in uncontrolled neuromuscular activity leading to death of insects and acarines. The selective toxicity of lotilaner between insects and acarines and mammals may be inferred by the differential sensitivity of the insects and acarines' GABA receptors versus mammalian GABA receptors.
-
Effectiveness:
In well-controlled European laboratory studies, CREDELIO began to kill fleas four hours after administration or infestation, with greater than 99% of fleas killed within eight hours after administration or infestation for 35 days. In a well-controlled U.S. laboratory study, CREDELIO demonstrated 100% effectiveness against adult fleas 12 hours after administration or infestation for 35 days.
In a 90-day well-controlled U.S. field study conducted in households with existing flea infestations of varying severity, the effectiveness of CREDELIO against fleas on Days 30, 60 and 90 compared to baseline was 99.5%,100% and 100%, respectively. Dogs with signs of flea allergy dermatitis showed improvement in erythema, papules, scaling, alopecia, dermatitis/pyodermatitis and pruritus as a direct result of eliminating fleas.
In a well-controlled laboratory study, CREDELIO killed fleas before they could lay eggs, thus preventing subsequent flea infestations for 30 days after the start of treatment of existing flea infestations.
In well-controlled laboratory studies, CREDELIO demonstrated > 97% effectiveness against Amblyomma americanum, Dermacentor variabilis, Ixodes scapularis and Rhipicephalus sanguineus ticks 48 hours after administration or infestation for 30 days. In a well-controlled European laboratory study, CREDELIO started killing Ixodes ricinus ticks within four hours after administration.
Palatability: In the U.S. field study, which included 567 doses administered to 198 dogs, 80.4% of dogs voluntarily consumed CREDELIO when offered by hand or in an empty bowl, an additional 13.6% consumed CREDELIO when offered with food, and 6.0% required placement of the chewable tablet in the back of the dog's mouth.
-
Animal Safety:
In a margin of safety study, CREDELIO was administered orally to 24 (8 dogs/group) 8-week-old Beagle puppies at doses of 43 mg/kg, 129 mg/kg, and 215 mg/kg (approximately 1, 3, and 5X the maximum labeled dose, respectively) every 28 days for eight consecutive doses. The 8 dogs in the control group (0X) were untreated. There were no clinically-relevant, treatment-related effects on clinical observations, physical and neurological examinations, body weights, food consumption, electrocardiograms, clinical pathology (hematology, clinical chemistries, coagulation profiles and urinalysis), gross pathology, histopathology, or organ weights. Blood concentrations of lotilaner confirmed systemic exposure of all treated dogs, although the exposure was less than dose proportional at 5X.
In a well-controlled field study, CREDELIO was used concurrently with other medications, such as vaccines, anthelmintics, antibiotics, steroids, NSAIDS, anesthetics, and antihistamines. No adverse reactions were observed from the concomitant use of CREDELIO with other medications.
- Storage Information:
-
How Supplied:
CREDELIO is available in five chewable tablet sizes for use in dogs: 56.25, 112.5, 225, 450, and 900 mg lotilaner.
Each chewable tablet size is available in color-coded packages of 1, 3 or 6 chewable tablets.
Approved by FDA under NADA # 141-494
Manufactured for:
Elanco US Inc
Greenfield, IN 46140 USA
Credelio.com
Credelio, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
Rev. date 05/2020
PA102967X
ElancoTM
-
Principal Display Panel - 3 Tablets 56.25 mg Box Label
3 Tablets
Dogs &
puppies4.4-6.0 lbs
Credelioâ„¢
(lotilaner)For the treatment and
prevention of flea infestations
and for the treatment and control
of tick infestations in dogs and
puppies 8 weeks of age and older56.25 mg chewable tablet
Kills fleas
Kills ticks
Monthly dose
Give with
foodCAUTION: Federal (USA) law restricts this drug to
use by or on the order of a licensed veterinarian.Approved by FDA under NADA # 141-494
ElancoTM
-
Principal Display Panel - 3 Tablets 112.5 mg Box Label
3 Tablets
Dogs &
puppies6.1-12.0 lbs
Credelioâ„¢
(lotilaner)For the treatment and
prevention of flea infestations
and for the treatment and control
of tick infestations in dogs and
puppies 8 weeks of age and older112.5 mg chewable tablet
Kills fleas
Kills ticks
Monthly dose
Give with
foodCAUTION: Federal (USA) law restricts this drug to
use by or on the order of a licensed veterinarian.Approved by FDA under NADA # 141-494
ElancoTM
-
Principal Display Panel - 3 Tablets 225 mg Box Label
3 Tablets
Dogs &
puppies12.1-25.0 lbs
Credelioâ„¢
(lotilaner)For the treatment and
prevention of flea infestations
and for the treatment and control
of tick infestations in dogs and
puppies 8 weeks of age and older225 mg chewable tablet
Kills fleas
Kills ticks
Monthly dose
Give with
foodCAUTION: Federal (USA) law restricts this drug to
use by or on the order of a licensed veterinarian.Approved by FDA under NADA # 141-494
ElancoTM
-
Principal Display Panel - 3 Tablets 450 mg Box Label
3 Tablets
Dogs &
puppies25.1-50.0 lbs
Credelioâ„¢
(lotilaner)For the treatment and
prevention of flea infestations
and for the treatment and control
of tick infestations in dogs and
puppies 8 weeks of age and older450 mg chewable tablet
Kills fleas
Kills ticks
Monthly dose
Give with
foodCAUTION: Federal (USA) law restricts this drug to
use by or on the order of a licensed veterinarian.Approved by FDA under NADA # 141-494
ElancoTM
-
Principal Display Panel - 3 Tablets 900 mg Box Label
3 Tablets
Dogs &
puppies50.1-100.0 lbs
Credelioâ„¢
(lotilaner)For the treatment and
prevention of flea infestations
and for the treatment and control
of tick infestations in dogs and
puppies 8 weeks of age and older900 mg chewable tablet
Kills fleas
Kills ticks
Monthly dose
Give with
foodCAUTION: Federal (USA) law restricts this drug to
use by or on the order of a licensed veterinarian.Approved by FDA under NADA # 141-494
ElancoTM
-
INGREDIENTS AND APPEARANCE
CREDELIOÂ
lotilaner tablet, chewableProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:58198-5452 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Lotilaner (UNII: HEH4938D7K) (Lotilaner - UNII:HEH4938D7K) Lotilaner 56.25 mg Product Characteristics Color White (beige with brownish spots) Score no score Shape ROUND (biconvex beveled edges) Size 7mm Flavor Imprint Code Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:58198-5452-3 16 in 1 BOX 1 NDC:58198-5452-1 1 in 1 CARTON 1 1 in 1 BLISTER PACK 2 NDC:58198-5452-4 10 in 1 BOX 2 NDC:58198-5452-2 2 in 1 CARTON 2 3 in 1 BLISTER PACK 3 NDC:58198-5452-5 7 in 1 BOX 3 1 in 1 CARTON 3 1 in 1 BLISTER PACK 4 NDC:58198-5452-6 16 in 1 BOX 4 NDC:58198-5452-7 1 in 1 CARTON 4 3 in 1 BLISTER PACK Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA141494 01/19/2018 CREDELIOÂ
lotilaner tablet, chewableProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:58198-5458 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Lotilaner (UNII: HEH4938D7K) (Lotilaner - UNII:HEH4938D7K) Lotilaner 112.5 mg Product Characteristics Color White (beige with brownish spots) Score no score Shape ROUND (biconvex beveled edges) Size 9mm Flavor Imprint Code Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:58198-5458-3 16 in 1 BOX 1 NDC:58198-5458-1 1 in 1 CARTON 1 1 in 1 BLISTER PACK 2 NDC:58198-5458-4 10 in 1 BOX 2 NDC:58198-5458-2 2 in 1 CARTON 2 3 in 1 BLISTER PACK 3 NDC:58198-5458-5 7 in 1 BOX 3 1 in 1 CARTON 3 1 in 1 BLISTER PACK 4 NDC:58198-5458-6 16 in 1 BOX 4 NDC:58198-5458-7 1 in 1 CARTON 4 3 in 1 BLISTER PACK Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA141494 01/19/2018 CREDELIOÂ
lotilaner tablet, chewableProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:58198-5456 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Lotilaner (UNII: HEH4938D7K) (Lotilaner - UNII:HEH4938D7K) Lotilaner 225 mg Product Characteristics Color White (beige with brownish spots) Score no score Shape ROUND (biconvex beveled edges) Size 12mm Flavor Imprint Code Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:58198-5456-3 16 in 1 BOX 1 NDC:58198-5456-1 1 in 1 CARTON 1 1 in 1 BLISTER PACK 2 NDC:58198-5456-4 10 in 1 BOX 2 NDC:58198-5456-2 2 in 1 CARTON 2 3 in 1 BLISTER PACK 3 NDC:58198-5456-5 7 in 1 BOX 3 1 in 1 CARTON 3 1 in 1 BLISTER PACK 4 NDC:58198-5456-6 16 in 1 BOX 4 NDC:58198-5456-7 1 in 1 CARTON 4 3 in 1 BLISTER PACK Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA141494 01/19/2018 CREDELIOÂ
lotilaner tablet, chewableProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:58198-5454 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Lotilaner (UNII: HEH4938D7K) (Lotilaner - UNII:HEH4938D7K) Lotilaner 450 mg Product Characteristics Color White (beige with brownish spots) Score no score Shape ROUND (biconvex beveled edges) Size 15mm Flavor Imprint Code Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:58198-5454-3 16 in 1 BOX 1 NDC:58198-5454-1 1 in 1 CARTON 1 1 in 1 BLISTER PACK 2 NDC:58198-5454-4 10 in 1 BOX 2 NDC:58198-5454-2 2 in 1 CARTON 2 3 in 1 BLISTER PACK 3 NDC:58198-5454-6 16 in 1 BOX 3 NDC:58198-5454-7 1 in 1 CARTON 3 3 in 1 BLISTER PACK Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA141494 01/19/2018 CREDELIOÂ
lotilaner tablet, chewableProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:58198-5451 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Lotilaner (UNII: HEH4938D7K) (Lotilaner - UNII:HEH4938D7K) Lotilaner 900 mg Product Characteristics Color White (beige with brownish spots) Score no score Shape ROUND (biconvex beveled edges) Size 19mm Flavor Imprint Code Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:58198-5451-3 16 in 1 BOX 1 NDC:58198-5451-1 1 in 1 CARTON 1 1 in 1 BLISTER PACK 2 NDC:58198-5451-4 10 in 1 BOX 2 NDC:58198-5451-2 2 in 1 CARTON 2 3 in 1 BLISTER PACK 3 NDC:58198-5451-6 16 in 1 BOX 3 NDC:58198-5451-7 1 in 1 CARTON 3 3 in 1 BLISTER PACK Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA141494 01/19/2018 Labeler - Elanco US Inc. (966985624) Establishment Name Address ID/FEI Business Operations Siegfried AG 482824026 API MANUFACTURE Establishment Name Address ID/FEI Business Operations Siegfried (Nantong) Pharmaceuticals Co., Ltd. 421329766 API MANUFACTURE Establishment Name Address ID/FEI Business Operations Elanco France SAS 736833104 MANUFACTURE Establishment Name Address ID/FEI Business Operations Allpack 484572565 LABEL, PACK Establishment Name Address ID/FEI Business Operations Elanco Clinton Laboratories 039138631 PACK, LABEL